Fosfomycun-trometamol
Phase 3Small molecule
Fosfomycun-trometamol is one of 34 small molecule programs targeting Urinary Tract Infection. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
39 competitors in Urinary Tract Infection
#DrugCompanyPhaseTrials
1Doribax
ShionogiApproved
Cipro
BayerApproved
Levaquin
WWim Janssens
Approved
Ivadantin
PProcter and Gamble
Approved
Estrace
Novo NordiskApproved
Voltaren
NovartisApproved
Acanya
PfizerApproved
Vesicare
AstellasApproved
Invanz
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Monurol
MMeitheal
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fosfomycun-trometamol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity Hospital, Rouen